FLT3 (F594_R595insR)

FLT3 · Variant type: indel · HGVS: p.F594_R595insR

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Gilteritinib	99.8%	0.3%	88.97
2	Brigatinib	99.3%	0.7%	82.96
3	Sunitinib	99.2%	0.8%	91.73
4	Pacritinib	99.1%	0.9%	88.64
5	Fostamatinib	97.8%	2.2%	96.74
6	Selpercatinib	95.3%	4.7%	96.72
7	Defactinib	95.2%	4.8%	92.68
8	Pralsetinib	94.8%	5.2%	93.43
9	Ponatinib	94.5%	5.5%	78.23
10	Quizartinib	94.4%	5.6%	99.50
11	Entrectinib	93.2%	6.8%	93.69
12	Nintedanib	91.3%	8.7%	90.23
13	Avapritinib	91.0%	9.0%	97.73
14	Fedratinib	87.9%	12.1%	96.21
15	Canertinib	85.4%	14.6%	96.49
16	Alectinib	83.8%	16.2%	95.49
17	Rabusertib	83.1%	16.9%	98.74
18	Osimertinib	79.4%	20.6%	97.24
19	Erlotinib	79.4%	20.6%	99.75
20	Pazopanib	76.0%	24.0%	97.49
21	Vandetanib	73.9%	26.1%	95.74
22	Sorafenib	73.9%	26.1%	96.72
23	Cabozantinib	66.9%	33.1%	92.73
24	Axitinib	61.9%	38.1%	93.23
25	Palbociclib	61.0%	39.0%	98.75

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Gilteritinib	99.8%	99.2%	+0.5%
Brigatinib	99.3%	98.1%	+1.2%
Sunitinib	99.2%	98.7%	+0.5%
Pacritinib	99.1%	93.6%	+5.5%
Fostamatinib	97.8%	97.2%	+0.6%
Selpercatinib	95.3%	96.1%	-0.8%
Defactinib	95.2%	94.6%	+0.6%
Pralsetinib	94.8%	97.6%	-2.8%
Ponatinib	94.5%	97.9%	-3.4%
Quizartinib	94.4%	97.9%	-3.5%
Entrectinib	93.2%	96.1%	-3.0%
Nintedanib	91.3%	95.2%	-3.9%
Avapritinib	91.0%	88.6%	+2.4%
Fedratinib	87.9%	98.2%	-10.2%
Canertinib	85.4%	86.3%	-0.9%
Alectinib	83.8%	84.5%	-0.8%
Rabusertib	83.1%	—	—
Osimertinib	79.4%	—	—
Erlotinib	79.4%	—	—
Pazopanib	76.0%	—	—
Vandetanib	73.9%	—	—
Sorafenib	73.9%	97.3%	-23.4%
Cabozantinib	66.9%	95.0%	-28.1%
Axitinib	61.9%	—	—
Palbociclib	61.0%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.1ms